Insight Molecular Diagnostics says Clinical Chemistry study shows 99.2% agreement between GraftAssure and rival NGS dd-cfDNA test at 0.5% threshold

• Insight Molecular Diagnostics announced a peer-reviewed Clinical Chemistry head-to-head study comparing its GraftAssure transplant test with a competing NGS assay.
• Results were first presented in 2025 at the European Renal Association and ESOT Congress, with additional data scheduled for the American Transplant Congress on June 20-24, 2026.
• The study found the two methods produced closely aligned clinical results in kidney transplant recipients, supporting interchangeability for routine rejection-risk monitoring.
• Digital PCR showed an analytical advantage in detecting very low biomarker levels, which could support earlier intervention and tighter longitudinal monitoring.
• The publication supports iMDx’s strategy to shift testing into hospital labs using kit-based workflows, targeting faster turnaround times and lower costs versus send-out testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606161605PRIMZONEFULLFEED9747989) on June 16, 2026, and is solely responsible for the information contained therein.